UPDATE : Monday, October 21, 2019
상단여백
FDA OKs Celltrion’s antibiotics generic by Lee Han-soo 2019-04-30 11:22
Huons, Genexine to cooperate on biopharmaceuticals by Lee Han-soo 2019-04-29 15:10
Techniques for biobetters get ever more advanced by Jeong Sae-im 2019-04-29 11:48
Prosecutors seek arrest warrant of Samsung Bioepis executives by Lee Han-soo 2019-04-26 17:19
FDA OKs Samsung Bioepis’ Etanercept biosimilar by Lee Han-soo 2019-04-26 14:22
라인
Foreign patients to join class-action suit against Kolon for Invossa by Jeong Sae-im 2019-04-25 15:39
Samsung Bioepis’ biosimilar sales in EU topped $170 million in Q1 by Lee Han-soo 2019-04-25 14:07
Samsung Biologics logs ₩23.4 billion operating loss in Q1 by Jeong Sae-im 2019-04-25 12:08
OECD guideline OKs Korean-developed eye irritation test by Lee Hye-seon 2019-04-22 15:33
Gene therapies’ potentials, challenges explained by Jeong Sae-im 2019-04-22 11:46
라인
Why is TissueGene CEO silent about Invossa mislabeling? by Jeong Sae-im 2019-04-19 14:37
‘How Korean pharma companies can succeed in US’ by Lee Han-soo 2019-04-18 14:41
Kolon desperate to keep Invossa license amid suspicion of data fabrication by Lee Hye-seon 2019-04-18 11:16
Patients to file class-action suit against Kolon over Invossa by Jeong Sae-im 2019-04-17 14:58
‘Invossa lacked clinical evidence to be commercialized’ by Jeong Sae-im 2019-04-17 12:45
라인
BIO KOREA 2019 aims to lead open innovation by Lee Han-soo 2019-04-17 12:42
Celltrion unveils P2 trial results for influenza antibody therapy by Lee Han-soo 2019-04-16 16:16
‘Kolon might have fabricated data to get Invossa approval’ by Jeong Sae-im 2019-04-16 11:07
[News Focus] Abbvie hits back at competitors selling Humira biosimilars in Europe by Lee Han-soo 2019-04-15 15:19
All Invossa products contained 293 cells, Kolon confirms by Jeong Sae-im 2019-04-15 11:31
여백
여백
여백
Back to Top